Please login to the form below

Not currently logged in
Email:
Password:

Roche and AbbVie's leukaemia drug set for filing by year-end

Blood cancer treatment venetoclax faces a tough market if approved

Roche HQ 

AbbVie and Roche says they plan to file for approval of their chronic lymphocytic leukaemia (CLL) candidate venetoclax by the end of the year after encouraging phase II data.

Venetoclax (also known as ABT-199) demonstrated a significant improvement in overall response rate (ORR) in CLL patients with a specific genetic mutation - 17p deletion - who are known to be have a poor prognosis.

The drug is an inhibitor of a protein called BCL-2 that is associated with B cell lymphomas and was awarded breakthrough status by the FDA earlier this year for this form of CLL.

The companies did not reveal details of the preliminary trial results but said they would "serve as the pivotal registration data for applications to the FDA, EMA and other health authorities."

The ongoing phase II trial (Study M13-982) assessed the safety and efficacy of venetoclax monotherapy in 157 patients with relapsed or refractory CLL, and in addition to ORR is also measuring complete and partial responses and progression-free survival (PFS).

It is scheduled to complete at the end of 2016 with full data available in May 2017, although AbbVie and Roche hope that the serious unmet medical need in CLL will allow them to get accelerated approval.

CLL is a slow-progressing cancer of the bone marrow and blood and is the most common leukaemia diagnosed in adults in western countries, with around 14,600 cases diagnosed in the US each year.

The 17p deletion mutation is present in between 3% and 10% of all CLL patients, but is disproportionately found in relapsed and refractory cases, where the incidence is 30% to 50% and reveals just how hard this form of the disease is to treat effectively.

If approved, venetoclax will compete in the market with other new therapies for CLL, including Johnson & Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib), which is specifically indicated for use in 17p deletion-positive patients.

Both Imbruvica and Zydelig were approved for CLL last year and have been tipped to become $1bn-plus products at peak. J&J booked $270m in Imbruvica sales in the first six months of this year, while Zydelig made $56m.

Article by
Phil Taylor

13th August 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...